Código QR

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Background: The kallikrein kinin system (KKS) is an established pharmacological target for the treatment and prevention of attacks in hereditary angioedema (HAE). Proteolytic activities of FXIIa and single-chain Factor XII (FXII) zymogen contribute to KKS activation and thereby may play roles in bot...

ver descrição completa

Na minha lista:
Principais autores: Allen C. Clermont, Nivetha Murugesan, Hannah J. Edwards, Daniel K. Lee, Natasha P. Bayliss, Edward J. Duckworth, Stephen J. Pethen, Sally L. Hampton, David Gailani, Edward P. Feener
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-12-01
Colecção:Frontiers in Pharmacology
Assuntos:
factor XIIa inhibitor
FXII zymogen
hereditary angioedema
kallikrein-kinin system
HAE
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2023.1287487/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados